Financial Report; Abbvie

Abbvie

3Q Revenues: $12.9 billion (+52%)

3Q Earnings: $2.3 billion (+23%)

YTD Revenues: $31.9 billion (+30%)

YTD Earnings: $4.6 billion (-10%)

Comments: Revenues from the Immunology Portfolio were $5.8 billion, an increase of 15%. Global Humira revenues were $5.1 billion, up 4%. U.S. Humira revenues were $4.2 billion, up 8%. Internationally, Humira sales were down 9% to $951 million due to biosimilar competition. Global Skyrizi sales were $435 million and Global Rinvoq sales were $215 million in the quarter. Revenues from the Hematologic Oncology Portfolio were $1.7 billion, an increase of 16.5%. Global Imbruvica sales were $1.4 billion, up 9%, with U.S. revenues of $1.1 billion and international profit sharing of $251 million. Global Venclexta sales were $352 million. Revenues from the Aesthetics Portfolio were $967 million. Global Botox Cosmetic revenues were $393 million, down 2%. Revenues from the Neuroscience Portfolio were $1.2 billion, with Global Botox Therapeutic sales of $523 million and Global Vraylar sales of $358 million.